Anthem Biosciences Ltd Upgraded to Hold by MarketsMOJO Amid Mixed Financials and Improved Technicals

Quality Assessment: Management Efficiency and Growth Metrics

Despite a challenging quarter ending December 2025, Anthem Biosciences continues to demonstrate strong operational fundamentals. The company reported a return on equity (ROE) of 19.93%, underscoring high management efficiency in deploying shareholder capital. This is a critical factor in the quality rating, as it indicates the company’s ability to generate profits relative to equity.

Long-term growth remains robust, with net sales expanding at an annualised rate of 29.80% and operating profit growing even faster at 44.32%. These figures highlight the company’s capacity to scale its operations and improve profitability over time, despite the recent quarterly dip in revenues and profits.

However, the latest quarter’s financial performance was disappointing: profit before tax excluding other income (PBT less OI) fell by 24.2% to ₹122.31 crores, net sales declined 18.3% to ₹423.15 crores, and profit after tax (PAT) dropped 14.1% to ₹110.87 crores compared to the previous four-quarter average. This short-term weakness tempers the overall quality outlook but does not overshadow the company’s longer-term growth trajectory and operational strength.

Valuation: Expensive but Justified by Growth Prospects

Anthem Biosciences currently trades at a price-to-book (P/B) ratio of 15.8, which is considered very expensive relative to typical pharmaceutical sector valuations. This premium valuation reflects investor expectations of sustained growth and profitability improvements. The company’s ROE of 17.7% over the past year supports this valuation to some extent, indicating efficient capital utilisation.

While the stock price has not generated a measurable return over the past year, profits have risen by 35%, suggesting that earnings growth is outpacing price appreciation. This divergence may indicate a potential re-rating opportunity if the company can return to consistent revenue and profit growth in upcoming quarters.

Financial Trend: Mixed Signals Amid Institutional Confidence

Financial trends for Anthem Biosciences present a mixed picture. The recent quarterly results were negative, with declines in key profitability metrics. However, the company remains net-debt free, which strengthens its balance sheet and provides flexibility for future investments or acquisitions.

Institutional investors have increased their stake by 3.87% over the previous quarter, now collectively holding 12.83% of the company’s shares. This growing institutional participation is a positive signal, as these investors typically conduct thorough fundamental analysis and tend to back companies with solid long-term prospects.

Comparing stock returns to the Sensex reveals Anthem Biosciences’ outperformance in the short term: a 5.18% gain over one week and 7.45% over one month, while the Sensex declined by 3.19% and 3.86% respectively. Year-to-date, the stock has surged 22.92%, contrasting with a 12.51% fall in the Sensex. These figures suggest renewed investor interest and momentum despite recent earnings challenges.

Technical Analysis: Shift to Mildly Bullish Momentum

The upgrade to Hold was significantly influenced by a positive change in Anthem Biosciences’ technical trend. The technical grade shifted from sideways to mildly bullish, reflecting improving market sentiment and momentum indicators.

Key technical signals include a bullish weekly MACD and Bollinger Bands, alongside a mildly bullish Dow Theory trend on both weekly and monthly charts. Although the monthly On-Balance Volume (OBV) remains bearish, the absence of a clear weekly OBV trend suggests a potential stabilisation in buying pressure.

The stock’s price action supports this technical optimism, with the current price at ₹800.30, up 2.08% on the day, trading near its 52-week high of ₹873.25 and well above the 52-week low of ₹579.45. Daily price movements between ₹777.05 and ₹809.90 indicate healthy volatility within an upward channel.

Market Capitalisation and Sector Context

As a mid-cap company in the Pharmaceuticals & Biotechnology sector, Anthem Biosciences occupies a niche with significant growth potential but also heightened volatility. Its Mojo Grade improvement from Sell to Hold reflects a more balanced risk profile, encouraging investors to monitor the stock closely for further developments.

Comparatively, the company’s year-to-date return of 22.92% far outpaces the Sensex’s negative 12.51%, signalling strong relative performance within the broader market. This outperformance, combined with improving technicals and institutional interest, supports the revised rating.

Outlook and Investor Considerations

While the recent quarterly results highlight near-term challenges, Anthem Biosciences’ strong management efficiency, net-debt free status, and healthy long-term growth rates provide a solid foundation for recovery. The technical indicators suggest that the stock is gaining positive momentum, which could translate into improved price performance if earnings stabilise.

Investors should weigh the company’s expensive valuation against its growth prospects and monitor institutional activity as a barometer of confidence. The upgrade to Hold reflects a cautious but constructive stance, recommending investors maintain positions while awaiting clearer signs of sustained financial improvement.

Given the company’s mid-cap status and sector dynamics, volatility is expected, but the combination of fundamental and technical factors now favours a more optimistic outlook than before.

Summary of Ratings and Scores

Anthem Biosciences Ltd’s current Mojo Score is 50.0, with a Mojo Grade of Hold, upgraded from Sell on 12 May 2026. The company’s market capitalisation is classified as mid-cap. Technical grades have improved notably, with weekly MACD and Bollinger Bands signalling bullish momentum, while monthly indicators remain mixed. Financially, the company boasts a high ROE of 19.93% and net-debt free status, but recent quarterly earnings declines have moderated enthusiasm.

Overall, the rating upgrade reflects a balanced view that recognises both the risks and opportunities inherent in Anthem Biosciences’ current position.

Limited Period Only. Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Get 72% Off →